QUESTION 102 Upfront fee allocated to separate performance obligations Biotech enters into a contract with Pharma for the license and development of a drug compound. The contract requires Biotech to perform research and development (R&D) services to get the drug compound through regulatory approval. Biotech receives an upfront fee of $50 million, fees for R&D services, and milestone-based payments upon the achievement of specified acts. Biotech concludes that the arrangement includes two separate performance obligations: (1) license of the intellectual property and (2) R&D services. There are no other performance obligations in the arrangement. How should Biotech allocate the consideration in the arrangement, including the $50 million upfront fee?